General Information of the Drug (ID: M6APDG03024)
Name
AMI-1
Synonyms
AMI1; AMI 1
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
Formula
C21H14N2Na2O9S2
InChI
1S/C21H16N2O9S2.2Na/c24-19-9-15(33(27,28)29)7-11-5-13(1-3-17(11)19)22-21(26)23-14-2-4-18-12(6-14)8-16(10-20(18)25)34(30,31)32;;/h1-10,24-25H,(H2,22,23,26)(H,27,28,29)(H,30,31,32);;/q;2*+1/p-2
InChIKey
MOUNHKKCIGVIDI-UHFFFAOYSA-L
PubChem CID
88489
TTD Drug ID
D09AFM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Protein arginine methyltransferase 1 (PRMT1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary Protein arginine methyltransferase 1 (PRMT1) is a therapeutic target for AMI-1. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMI-1 through regulating the expression of Protein arginine methyltransferase 1 (PRMT1). [1], [2]
References
Ref 1 m(6) A deposition is regulated by PRMT1-mediated arginine methylation of METTL14 in its disordered C-terminal region. EMBO J. 2021 Mar 1;40(5):e106309. doi: 10.15252/embj.2020106309. Epub 2021 Jan 18.
Ref 2 National Cancer Institute Drug Dictionary (drug name GSK6097608).